Drug Trial Radar · NCT05544565
3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Mar 22, 2023
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 month, up to 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Antibiotic therapies currently recommended for the treatment of acute pyelonephritis (AP) in children, whether fully by the oral route or initially intravenous (IV, 3 days) followed by the oral route, have a duration of 7 to 14 days (10 days in France). In children with no prior urological malformation, the global clinical and microbiological cure rate after antibiotic treatment completion is around 95%. Recurrence occurs in less than 5% of cases in the 3 months following AP. Renal scarring, when documented, concerns 15% of children 6 months after treatment. Renal scarring can be associated with chronic renal disease. The investigators hypothesize that 3 days of IV treatment is equivalent to extending to 10 days with an oral to treat AP in children. The investigators also hypothesize that while achieving equivalent clinical and prevention of re-infections in the following 3 months, 3 days of IV treatment reduces the risk of acquisition of resistant strains of Enterobacteriaceae and increases the gut microbotia diversity compared to extending to 10 days with an oral therapy.
Conditions
- Pyelonephritis Acute
Interventions
IV Antibacterial AgentsDrug
Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
Orally antibacterial agentsDrug
Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
Fecal/Rectal SwabProcedure
Collected by the nurse or the physician (D0,D3,D10 or 17 and D31 or D38), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
PCT assayProcedure
Dosage of procalcitonin (if not performed in standard care) at D0
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence of febrile urinary tract infectionTime frame: 28 days (± 3 days) after the completion of antibiotic treatment.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
GHEF Site Marne la vallée
Jossigny, France · Not yet recruiting
CHU Toulouse
Toulouse, France · Not yet recruiting
CH Sud Francilien
Corbeil-Essonnes, Essonne, France · Not yet recruiting
Paris-Saclay hospital
Orsay, Essonne, France · Recruiting
Antoine Beclère Hospital
Clamart, Haut de Seine, France · Not yet recruiting
Ambroise Paré hospital
Boulogne, Hauts de Seine, France · Recruiting
Children-Teenager hospital
Nantes, Loire Atlantique, France · Not yet recruiting
Jeanne Flandre Hospital
Lille, Nord, France · Not yet recruiting
Robert Debré Hospital
Paris, Paris, France · Not yet recruiting
Robert Debré Hospital
Paris, Paris, France · Not yet recruiting
Meaux Hospital
Meaux, Seine et Marne, France · Not yet recruiting
Jean Verdier Hospital
Bondy, Seine St Denis, France · Not yet recruiting
Intercomunal Créteil Hospital
Créteil, Val de Marne, France · Not yet recruiting
Kremlin Bicêtre Hospital
Le Kremlin-Bicêtre, Val de Marne, France · Not yet recruiting
Andre mignot hospital
Le Chesnay, Yvelines, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.